The predominant molecular symptom of aging is the accumulation of altered gene products.
Moreover, several conditions including protein, lipid or glucose oxidation disrupt redox …

Introduction With new anticancer therapies, many patients can have a long life expectancy.
Treatment-related comorbidities become an issue for cancer survivors. Cardiac toxicity …

OBJECTIVE: Cardiac toxicity remains an important side effect of anthracyclines. New drug
formulations (eg, pegylated liposomal doxorubicin [PL-DOX]) seem to be a successful …

Background and purpose: A pilot study of high dose coenzyme Q10 (CoQ10)/vitamin E
therapy in Friedreich's ataxia (FRDA) patients resulted in significant clinical improvements in …

Evaluation of therapeutic agents for Friedreich Ataxia (FA) has been limited by a lack of
adequate markers of disease progression. We assessed the capacity of health related …

Background: Friedreich's ataxia is an autosomal recessive neurodegenerative disease
where impaired mitochondrial function and excessive production of free radicals play a …

The inherited ataxias are a large, heterogeneous group of neurodegenerative disorders
caused by a variety of gene mutations, the effects of which are exerted through different …

Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but
have not been tested in clinical trials. We found that a majority of patients in our cohort …

In systemic diseases such as amyloidosis, sarcoidosis, Friedreich's ataxia, Fabry's disease
and muscular dystrophy the clinician has to judge the presence and the amount of cardiac …

In this pilot study, we examined the feasibility and toxicity in 16 elderly women age≥ 65
receiving six cycles of pegylated liposomal doxorubicin (PL-DOX) cyclophosphamide as …